April 1 - 5, 2025 | Vienna, Austria

Join Taconic Biosciences at AD/PD 2025: Advances in Science & Therapy

Taconic Biosciences is excited to attend AD/PD 2025, where leaders in the field will gather to explore groundbreaking research and innovative treatments for Alzheimer's and Parkinson's Disease.

Connect with us at the event

Are you attending this year's international conference on Alzheimer's and Parkinson's Disease and related neurological disorders? We'd love to meet with you! Stop by our scientific poster to learn more about the latest advancements in translational mouse models of Alzheimer's and Parkinson's disease, or complete the form below to request a meeting to discuss your research needs.

Featured Presentation

Thursday, April 3, 2025 | 4:20 PM - 5:20 PM | Hall A

Symposium Title: Latest Advancements in Translational Mouse Models of Alzheimer’s Disease, Tauopathies & Parkinson’s Disease

Presentation Title: A new amyloid-beta and tau co-pathology mouse model of Alzheimer's disease

Join Drs. Laura Griffin and Anastasia Noël as they present innovative in vivo and ex vivo data on cutting-edge models of tau pathology and amyloid-beta/tau co-pathology. Learn how these models translate to human Alzheimer’s disease and other tauopathies.

An interactive Q&A session will follow, offering a unique opportunity to engage directly with the experts. Don’t miss out on the latest breakthroughs in clinically relevant and translational disease models.

Biospective in collaboration with Taconic Biosciences

Featured Poster

Additional details coming soon

Poster Board #2898: 3D Whole-Brain Imaging of Parenchymal/Vascular Amyloid Plaque Architecture During Disease Progression in a Transgenic Mouse Model of Alzheimer's Disease

This study uses high-throughput light sheet fluorescence microscopy and AI-driven image analysis to map age- and sex-dependent amyloid plaque accumulation in a transgenic mouse model of Alzheimer’s disease. Findings highlight faster amyloidosis progression in female mice and delayed vascular plaque deposition, underscoring the importance of considering sex and age in preclinical drug evaluation.

Gubra in collaboration with Taconic Biosciences

Featured Taconic Presenter

Laura Griffin, PhD

Field Applications Scientist

Dr. Laura Griffin has been working with preclinical models for a decade and is experienced in choosing appropriate models for various research applications. She obtained her PhD in Food Science and Technology at Virginia Tech, where she focused on the mechanisms by which dietary bioactive compounds influence the onset of metabolic syndrome using preclinical models. As a postdoctoral fellow at the Plants for Human Health Institute, her research shifted to focus on the impact of the gut microbiome on the metabolism of bioactive compounds. In addition to her expertise in metabolic diseases in preclinical models, Dr. Griffin is also versed in laboratory animal diets and their usage in preclinical applications.

Featured Resources

Therapeutic Area

Neuroscience Portfolio

Taconic provides easy access to models and services for the study of neuronal disease and signaling, many of which are available exclusively from Taconic with rights to use.

Learn More